サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1759485

アルテスネート注射剤の世界市場：純度・用途・エンドユーザー・流通経路・地域別 (～2032年)

Global Artesunate Injection Market Research Report Information by Purity, by Application, by End User, by Distribution Channel, by Region Industry Forecast till 2032

出版日
ページ情報
英文 107 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
アルテスネート注射剤の世界市場：純度・用途・エンドユーザー・流通経路・地域別 (～2032年)
出版日: 2025年05月22日
発行: Market Research Future
ページ情報: 英文 107 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のアルテスネート注射剤の市場規模は、2023年の約8,500万米ドルから、2024年から2032年にかけての予測期間中に0.9%のCAGRで緩やかに成長すると予測されています。

主な成長要因としては、マラリアの罹患率の増加、即効性のある注射療法の選好の高まり、製造・流通システムの進歩が挙げられます。さらに、世界的な啓発活動による認知度の向上と早期診断の促進も、治療率の改善に良い影響を与えています。

しかし、いくつかの制約が市場の可能性を妨げています。製造・治療コストの高さ、地域によって供給が不安定であること、厳格な規制承認プロセスが障害となっています。さらに、知的財産に関する複雑な問題や、他の抗マラリア薬との競合も、市場の成長に対する圧力となっています。

こうした制約にもかかわらず、成長の機会は存在します。たとえば、遠隔医療プラットフォームの普及により、マラリア流行地域の遠隔地における診断・治療へのアクセスが拡大しています。加えて、官民の連携強化によって、マラリア関連の医療ソリューションへの資金提供が増加しています。また、地域ごとの製造拠点の整備がサプライチェーンの安定化に寄与しており、医療インフラ全体の進展がアルテスネート注射剤へのアクセス向上を促進しています。

地域別展望

北米では、世界的な健康意識の高まりを背景に、アルテスネート注射剤への需要が増加しています。これは主に、マラリア流行地域への渡航者の増加によるものです。カナダや米国ではマラリアの土着感染は見られないものの、海外からの輸入症例が増加傾向にあり、重症化を防ぐために迅速かつ効果的な治療法であるアルテスネートへのアクセスが求められています。

欧州では、欧州医薬品庁 (EMA) により、アルテスネートが重症マラリアに対する非常に有効な治療薬として認められており、多くの国で国家治療ガイドラインに組み込まれています。しかし、規制の複雑さやコストに関する課題が残っており、地域全体でのより広範な導入には制限があります。

アジア太平洋地域では、世界保健機関（WHO）が重症マラリアの第一選択薬としてアルテスネートを推奨していることを受けて、その導入が広がっています。この推奨に基づき、マラリア流行国では公的な医療プロトコルに正式に組み込まれており、実際の臨床現場での使用が拡大しています。

南米では、ペルー、ブラジル、コロンビアなどアマゾン流域の国々でマラリアの感染率が依然として高く、特に重症例においてアルテスネートが各国のマラリア対策プログラムで極めて重要な役割を果たしています。

中央アフリカ諸国、特にコンゴ民主共和国などでは、非常に高いマラリア罹患率に直面しており、アルテスネートは最前線の治療薬として不可欠な存在となっています。

当レポートでは、世界のアルテスネート注射剤の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

  • 促進要因
    • マラリアの有病率の増加
    • 注射による治療への需要の高まり
    • 製造・流通技術の進歩
    • 啓発活動と教育水準の向上
  • 抑制要因
    • アルテスネート注射剤の高コスト
    • アルテスネート注射剤の高コスト
    • 規制上の課題および承認プロセスの長期化
    • 知的財産権および特許に関する問題
    • 他の抗マラリア治療薬との競合
  • 機会
    • 遠隔診療サービスの拡大による遠隔地での診断・治療の可能性向上
    • マラリア研究に対する官民連携による資金調達の増加
    • 治療効果を高めるための併用療法の開発
    • 供給網の強化を目的とした地域の製造拠点の台頭
    • ヘルスケア業界全体への影響
    • 世界のアルテスネート注射剤市場への影響
    • アルテスネート注射剤市場のサプライチェーンへの影響
    • アルテスネート注射剤市場の需要への影響
    • アルテスネート注射剤市場の価格への影響

第5章 市場要因分析

  • サプライチェーン分析
  • ポーターのファイブフォースモデル

第6章 世界のアルテスネート注射剤市場：純度別

  • アルテスネート0.99
  • アルテスネート0.98

第7章 世界のアルテスネート注射剤市場：用途別

  • マラリア
  • 重症マラリア
  • 脳マラリア
  • 合併症のないマラリア

第8章 世界のアルテスネート注射剤市場：エンドユーザー別

  • 病院
  • クリニック
  • 薬局
  • 政府機関
  • 非政府組織

第9章 世界のアルテスネート注射剤市場：流通チャネル別

  • 直接販売
  • 販売業者および卸売業者
  • 小売薬局
  • オンライン販売

第10章 世界のアルテスネート注射剤市場：地域別

  • 概要
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ

第11章 競合情勢

  • 市場シェア分析
  • 競合ダッシュボード
  • 主な展開・成長戦略

第12章 企業プロファイル

  • AMIVAS
  • ADVACARE PHARMA
  • ZYDUS CADILA
  • INTAS PHARMACEUTICAL
  • SYSTACARE REMEDIES
  • LEXICARE PHARMA
  • CIPLA
  • GUILIN PHARMA
  • IPCA LABORATORIES
  • WATRAN PHARMACEUTICALS PVT. LTD
図表

LIST OF TABLES

  • TABLE 1 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD)
  • TABLE 2 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 3 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 4 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 5 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2018-2032 (USD)
  • TABLE 6 NORTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD)
  • TABLE 7 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD)
  • TABLE 8 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 9 NORTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 10 NORTH AMERICA ARTESUNATE INJECTION MARKET, DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 11 US ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 12 US: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD)
  • TABLE 13 US ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD)
  • TABLE 14 US ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD)
  • TABLE 15 CANADA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 16 CANADA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 17 CANADA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 18 CANADA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 19 EUROPE: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 20 EUROPE ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 21 EUROPE: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 22 EUROPE ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 23 EUROPE ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 24 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 25 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 26 ASIA PACIFIC: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 27 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 28 ASIA PACIFIC ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 29 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 30 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 31 SOUTH AMERICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 32 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 33 SOUTH AMERICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 34 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY COUNTRY, 2018-2032 (USD )
  • TABLE 35 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY PURITY, 2018-2032 (USD )
  • TABLE 36 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET, BY APPLICATION, 2018-2032 (USD )
  • TABLE 37 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY END USER, 2018-2032 (USD )
  • TABLE 38 MIDDLE EAST & AFRICA ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD )
  • TABLE 39 LAUNCH DEVELOPMENTS
  • TABLE 40 AMIVAS: PRODUCT OFFERED
  • TABLE 41 ADVACARE PHARMA: TYPES OFFERED
  • TABLE 42 ZYDUS CADILA: TYPES OFFERED
  • TABLE 43 INTAS PHARMACEUTICAL: TYPES OFFERED
  • TABLE 44 SYSTACARE REMEDIES: TYPES OFFERED
  • TABLE 45 LEXICARE PHARMA: TYPES OFFERED
  • TABLE 46 CIPLA: TYPES OFFERED
  • TABLE 47 GUILIN PHARMA: TYPES OFFERED
  • TABLE 48 IPCA LABORATORIES: TYPES OFFERED
  • TABLE 49 WATRAN PHARMACEUTICALS PVT. LTD: TYPES OFFERED

LIST OF FIGURES

  • FIGURE 1 GLOBAL ARTESUNATE INJECTION MARKET: STRUCTURE
  • FIGURE 2 GLOBAL ARTESUNATE INJECTION MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)
  • FIGURE 3 DRIVER IMPACT ANALYSIS (2024-2032)
  • FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)
  • FIGURE 5 SUPPLY CHAIN ANALYSIS: GLOBAL ARTESUNATE INJECTION MARKET
  • FIGURE 7 PORTER'S FIVE FORCES MODEL: GLOBAL ARTESUNATE INJECTION MARKET
  • FIGURE 8 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 9 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY, 2023 (% SHARE)
  • FIGURE 10 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 11 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION, 2023 (% SHARE)
  • FIGURE 12 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 13 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER, 2023 (% SHARE)
  • FIGURE 14 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, SEGMENT ATTRACTIVENESS ANALYSIS
  • FIGURE 15 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL, 2023 (% SHARE)
  • FIGURE 16 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION, 2023 (% SHARE)
  • FIGURE 17 NORTH AMERICAN MARKET: SWOT ANALYSIS
  • FIGURE 18 NORTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 19 EUROPE MARKET: SWOT ANALYSIS
  • FIGURE 20 EUROPE: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 21 ASIA PACIFIC MARKET: SWOT ANALYSIS
  • FIGURE 22 ASIA PACIFIC: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 23 SOUTH AMERICA MARKET: SWOT ANALYSIS
  • FIGURE 24 SOUTH AMERICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 25 MIDDLE EAST & AFRICA MARKET: SWOT ANALYSIS
  • FIGURE 26 MIDDLE EAST & AFRICA: ARTESUNATE INJECTION MARKET SHARE, BY COUNTRY, 2023 (% SHARE)
  • FIGURE 27 GLOBAL ARTESUNATE INJECTION PLAYERS: COMPETITIVE ANALSIS, 2023
  • FIGURE 28 COMPETITOR DASHBOARD: GLOBAL ARTESUNATE INJECTION
  • FIGURE 29 AMIVAS: SWOT ANALYSIS
  • FIGURE 30 ADVACARE PHARMA: SWOT ANALYSIS
  • FIGURE 31 ZYDUS CADILA: SWOT ANALYSIS
  • FIGURE 32 INTAS PHARMACEUTICAL: SWOT ANALYSIS
  • FIGURE 33 SYSTACARE REMEDIES: SWOT ANALYSIS
  • FIGURE 34 LEXICARE PHARMA: SWOT ANALYSIS
  • FIGURE 35 CIPLA: SWOT ANALYSIS
  • FIGURE 36 GUILIN PHARMA: SWOT ANALYSIS
  • FIGURE 37 IPCA LABORATORIES: SWOT ANALYSIS
  • FIGURE 38 WATRAN PHARMACEUTICALS PVT. LTD: SWOT ANALYSIS
目次
Product Code: MRFR/HC/38057-HCR

Global Artesunate Injection Market Research Report Information by Purity (Artesunate 0.99, Artesunate 0.98), by Application (Malaria, Severe Malaria, Cerebral Malaria, Uncomplicated Malaria, Other Applications), by End User (Hospitals, Clinics, Pharmacies, Government Institutions, Non-Governmental Organizations), by Distribution Channel (Direct Sales, Distributors and Wholesalers, Retail Pharmacies, and Online Sales), by Region (North America, Europe, APAC, South America, MEA) Industry Forecast till 2032

Market Analysis

In 2023, the global artesunate injection market reached a valuation of approximately USD 85 million. From 2024 to 2032, the market is anticipated to grow at a modest compound annual growth rate (CAGR) of 0.9%. Key growth factors include the increasing burden of malaria, the rising preference for injectable therapies that offer rapid action, and advancements in manufacturing and distribution systems. In addition, improved awareness and early diagnosis due to global education initiatives have positively influenced treatment rates.

However, several limitations hinder the market's potential. High production and treatment costs, inconsistent availability in various regions, and stringent regulatory approval processes create roadblocks. Complex intellectual property issues and competition from alternative antimalarial drugs also add pressure to market growth.

Despite these restraints, opportunities exist. The rise of telehealth platforms is helping expand access to diagnosis and treatment in remote, malaria-affected regions. Furthermore, increased collaboration between public and private sectors is resulting in greater funding for malaria-related healthcare solutions. The development of regional manufacturing centers is improving supply chain stability, and general progress in healthcare infrastructure is facilitating better access to artesunate injections. Together, these trends are shaping market dynamics and influencing future pricing, accessibility, and overall demand for artesunate therapies.

Industry Segmentation

Depending on the purity type, the global artesunate injection market is divided into Artesunate 0.99 and Artesunate 0.98.

The global artesunate injection market is divided into end user industry, such as hospitals, clinics, pharmacies, government institutions, non-governmental organizations.

The application type of the global market comprises malaria, severe malaria, cerebral malaria, uncomplicated malaria, other applications.

Based on the distribution channel, the global market has been categorized into direct sales, distributors and wholesalers, retail pharmacies, and online sales.

In terms of regions, the global market comprises, Middle East & Africa, Europe, North America, South America, and Asia Pacific.

Regional Perspectives

In North America, increasing global health awareness has contributed to rising demand for artesunate injections, primarily due to the growing number of travelers visiting malaria-endemic countries. Although malaria is not endemic in Canada or the United States, the region has witnessed a rise in imported cases, necessitating access to rapid and effective treatments like artesunate to prevent severe complications.

In Europe, artesunate has gained recognition from the European Medicines Agency (EMA) as a highly effective treatment for severe malaria. Consequently, many countries have incorporated it into their national treatment guidelines. However, regulatory complexities and cost-related challenges still limit its broader use across the continent.

The Asia-Pacific region has seen expanded adoption of artesunate, largely driven by the World Health Organization's (WHO) recommendation endorsing it as the first-line treatment for severe malaria. This has led to its inclusion in official healthcare protocols throughout malaria-prone nations in the region.

In South America, nations within the Amazon Basin, including Peru, Brazil, and Colombia, continue to experience high rates of malaria transmission. Artesunate plays a crucial role in national malaria response programs, especially for severe infections.

Central African countries like the Democratic Republic of the Congo (DRC) face a heavy malaria burden, where artesunate remains an essential component of frontline treatment.

Major Competitors

Cipla, Guilin Pharma, IPCA Laboratories, AMIVAS, Advacare Pharma, Zydus Cadila, Intas Pharmaceutical, Systacare Remedies, Lexicare Pharma, Watran Pharmaceuticals Pvt. Ltd. are the leading companies in the Global Artesunate Injection Market Research.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA FLOW
    • 3.2.1 DATA MINING PROCESS
  • 3.3 PURCHASED DATABASE:
  • 3.4 SECONDARY SOURCES:
    • 3.4.1 SECONDARY RESEARCH DATA FLOW:
  • 3.5 PRIMARY RESEARCH:
    • 3.5.1 PRIMARY RESEARCH DATA FLOW:
    • 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
    • 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
  • 3.6 APPROACHES FOR MARKET END USER ESTIMATION:
    • 3.6.1 REVENUE ANALYSIS APPROACH
    • 3.6.2 DATA FORECASTING
    • 3.6.3 DATA FORECASTING TECHNIQUE
  • 3.7 DATA MODELING
    • 3.7.1 MICROECONOMIC FACTOR ANALYSIS:
    • 3.7.2 DATA MODELING:
  • 3.8 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

  • 4.1 INTRODUCTION
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF MALARIA
    • 4.2.2 GROWING DEMAND FOR INJECTABLE TREATMENTS
    • 4.2.3 ADVANCEMENTS IN MANUFACTURING AND DISTRIBUTION
    • 4.2.4 GROWING AWARENESS AND EDUCATION
  • 4.3 RESTRAINTS
    • 4.3.1 HIGH COST OF ARTESUNATE INJECTIONS
    • 4.3.2 LIMITED AVAILABILITY IN CERTAIN REGIONS
    • 4.3.3 REGULATORY CHALLENGES AND LENGTHY APPROVAL PROCESSES
    • 4.3.4 INTELLECTUAL PROPERTY AND PATENT ISSUES
    • 4.3.5 COMPETING ANTIMALARIAL THERAPIES
  • 4.4 OPPORTUNITY
    • 4.4.1 EXPANSION OF TELEHEALTH SERVICES FOR REMOTE DIAGNOSIS AND TREATMENT
    • 4.4.2 INCREASED PUBLIC-PRIVATE PARTNERSHIPS FOR FUNDING MALARIA RESEARCH
    • 4.4.3 DEVELOPMENT OF COMBINATION THERAPIES TO ENHANCE TREATMENT EFFICACY
    • 4.4.4 EMERGENCE OF REGIONAL MANUFACTURING HUBS TO BOOST SUPPLY CHAIN RESILIENCE
    • 4.4.5 IMPACT ON OVERALL HEALTHCARE SECTOR
    • 4.4.6 IMPACT ON GLOBAL ARTESUNATE INJECTION MARKET
    • 4.4.7 IMPACT ON THE SUPPLY CHAIN OF THE ARTESUNATE INJECTION MARKET
    • 4.4.8 IMPACT ON MARKET DEMAND OF ARTESUNATE INJECTION MARKET
    • 4.4.9 IMPACT ON PRICING OF ARTESUNATE INJECTION MARKET

5 MARKET FACTOR ANALYSIS

  • 5.1 SUPPLY CHAIN ANALYSIS
    • 5.1.1 RAW MATERIAL SUPPLIERS
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION AND LOGISTICS
    • 5.1.4 RETAIL AND CONSUMPTION
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 BARGAINING POWER OF SUPPLIERS
    • 5.2.2 BARGAINING POWER OF BUYERS
    • 5.2.3 THREAT OF NEW ENTRANTS
    • 5.2.4 THREAT OF SUBSTITUTES
    • 5.2.5 INTENSITY OF RIVALRY

6 GLOBAL ARTESUNATE INJECTION MARKET, BY PURITY

  • 6.1 INTRODUCTION
  • 6.2 ARTESUNATE 0.99
  • 6.3 ARTESUNATE 0.98

7 GLOBAL ARTESUNATE INJECTION MARKET, BY APPLICATION

  • 7.1 INTRODUCTION
    • 7.1.1 MALARIA
    • 7.1.2 SEVERE MALARIA
    • 7.1.3 CEREBRAL MALARIA
    • 7.1.4 UNCOMPLICATED MALARIA

8 GLOBAL ARTESUNATE INJECTION MARKET, BY END USER

  • 8.1 INTRODUCTION
    • 8.1.1 HOSPITALS
    • 8.1.2 CLINICS
    • 8.1.3 PHARMACIES
    • 8.1.4 GOVERNMENT INSTITUTIONS
    • 8.1.5 NON-GOVERNMENTAL ORGANIZATIONS

9 GLOBAL ARTESUNATE INJECTION MARKET, BY DISTRIBUTION CHANNEL

  • 9.1 INTRODUCTION
    • 9.1.1 DIRECT SALES
    • 9.1.2 DISTRIBUTORS AND WHOLESALERS
    • 9.1.3 RETAIL PHARMACIES
    • 9.1.4 ONLINE SALES

10 GLOBAL ARTESUNATE INJECTION MARKET, BY REGION

  • 10.1 OVERVIEW
  • 10.2 NORTH AMERICA
  • 10.3 EUROPE
  • 10.4 ASIA PACIFIC
  • 10.5 SOUTH AMERICA
  • 10.6 MIDDLE EAST & AFRICA

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 MARKET SHARE ANALYSIS, 2023
  • 11.3 COMPETITOR DASHBOARD
  • 11.4 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 11.4.1 LAUNCH DEVELOPMENTS

12 COMPANY PROFILES

  • 12.1 AMIVAS
    • 12.1.1 COMPANY OVERVIEW
    • 12.1.2 TYPES OFFERED
    • 12.1.3 SWOT ANALYSIS
    • 12.1.4 KEY STRATEGY
  • 12.2 ADVACARE PHARMA
    • 12.2.1 COMPANY OVERVIEW
    • 12.2.2 TYPES OFFERED
    • 12.2.3 SWOT ANALYSIS
    • 12.2.4 KEY STRATEGY
  • 12.3 ZYDUS CADILA
    • 12.3.1 COMPANY OVERVIEW
    • 12.3.2 TYPES OFFERED
    • 12.3.3 SWOT ANALYSIS
    • 12.3.4 KEY STRATEGY
  • 12.4 INTAS PHARMACEUTICAL
    • 12.4.1 COMPANY OVERVIEW
    • 12.4.2 TYPES OFFERED
    • 12.4.3 SWOT ANALYSIS
    • 12.4.4 KEY STRATEGY
  • 12.5 SYSTACARE REMEDIES
    • 12.5.1 COMPANY OVERVIEW
    • 12.5.2 TYPES OFFERED
    • 12.5.3 SWOT ANALYSIS
    • 12.5.4 KEY STRATEGY
  • 12.6 LEXICARE PHARMA
    • 12.6.1 COMPANY OVERVIEW
    • 12.6.2 TYPES OFFERED
    • 12.6.3 SWOT ANALYSIS
  • 12.7 CIPLA
    • 12.7.1 COMPANY OVERVIEW
    • 12.7.2 TYPES OFFERED
    • 12.7.3 SWOT ANALYSIS
    • 12.7.4 KEY STRATEGY
  • 12.8 GUILIN PHARMA
    • 12.8.1 COMPANY OVERVIEW
    • 12.8.2 TYPES OFFERED
    • 12.8.3 SWOT ANALYSIS
  • 12.9 IPCA LABORATORIES
    • 12.9.1 COMPANY OVERVIEW
    • 12.9.2 TYPES OFFERED
    • 12.9.3 SWOT ANALYSIS
  • 12.10 WATRAN PHARMACEUTICALS PVT. LTD
    • 12.10.1 COMPANY OVERVIEW
    • 12.10.2 TYPES OFFERED
    • 12.10.3 SWOT ANALYSIS